OTC Triptans
This brief editorial on the proposed POM 2 P switch of triptans is from The Lancet Neurology
posted by John Blenkinsopp @ 20:24
Blenkinsopp Pharma Consultancy
The weblog of Professor Alison Blenkinsopp and Dr John Blenkinsopp. Healthcare starts with self-care.
About Me
- Name: John Blenkinsopp
- Location: Leeds, United Kingdom
I work as a Senior Research Fellow in the Department of Medicines Management at Keele University. In addition, I run a consultancy business (Blenkinsopp Pharma Consultancy, http://www.blenkinsopp.co.uk ) which specialises in the reclassification of medicines to make them more easily accessible to the public. My work at Keele University involves working with IMPACT DETAILING, which provides an academic detailing capability (see http://www.impactdetailing.org.uk for more informaition). I am also involved in Creative Medicines Management (http://www.creamm.co.uk ) a spin-off business of the Department of Medicines Management. Finally, I am a Non-Executive Director of LUTO Research Ltd. (http://www.luto.co.uk )a company specialising in user testing of Patient Information Leaflets (PILs). In my spare time I paint and etch!
Previous Posts
Symptoms In The Pharmacy: A Guide To The Management Of Common Illness
Thursday, September 29, 2005
This brief editorial on the proposed POM 2 P switch of triptans is from The Lancet Neurology
0 Comments:
Post a Comment
<< Home